Press release
Masimo Reports Fourth Quarter and Full-Year 2022 Financial Results
Fourth Quarter 2022 Highlights: Consolidated revenue was $617.0 million; Healthcare revenue was $351.9 million, representing 7.4% reported growth and 10.1%
About this update from Masimo Corporation
[{"type":"text","content":"\nFourth Quarter 2022 Highlights:\n\n\nConsolidated revenue was $617.0 million;\n\n\nHealthcare revenue was $351.9 million, representing 7.4% reported growth and 10.1% constant currency growth; and\n\n\nNon-healthcare revenue was $265.1 million.\n\n\nFull-Year 2022 Highlights:\n\n\nConsolidated revenue was $2,035.8 million;\n\n\nHealthcare revenue was $1,340.3 million, representing 8.2% reported growth and 10.6% constant currency growth; and\n\n\nNon-healthcare revenue was $695.5 million.\n\n\n IRVINE, Calif.--(BUSINESS WIRE)--\nMasimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended December 31, 2022.\n\nFourth Quarter 2022 Results:\n\nConsolidated revenue was $617.0 million, representing 88.3% reported growth. Healthcare revenue was $351.9 million, representing 7.4% reported growth and 10.1% growth on a constant currency basis. Non-healthcare revenue was $265.1 million.\n\nExcluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 78,800.\n\nConsolidated GAAP operating income was $73.5 million. Consolidated non-GAAP operating income was $104.4 million. Consolidated GAAP net income was $41.1 million, or $0.76 per diluted share, which includes expenses related to the Sound United acquisition. Consolidated non-GAAP net income was $71.3 million, or $1.32 per diluted share.\n\nFull-Year 2022 Results:\n\nConsolidated revenue was $2,035.8 million, representing 64.3% reported growth. Healthcare revenue was $1,340.3 million, representing 8.2% reported growth and 10.6% growth on a constant currency basis. Non-healthcare revenue was $695.5 million.\n\nExcluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 307,600.\n\nConsolidated GAAP operating income was $210.0 million. Consolidated non-GAAP operating income was $362.2 million. Consolidated GAAP net income was $143.5 million, or $2.60 per diluted share, which includes expenses related to the Sound United acquisition. Consolidated non-GAAP net income was $253.2 million, or $4.59 per diluted share.\n\nJoe Kiani, Chairman and Chief Executive Officer of Masimo, said, “2022 was a momentous year for Masimo. Our healthcare business outperformed expectations. We continued to innovate and deliver clinically proven new products in our pro...